QT Imaging said it intends to go public this year through a de-SPAC transaction. QT Imaging has engaged ARC Group to advise on the process.
QT is a privately held developer of innovative, proprietary body imaging technology, offering patients a safe, radiation-free, accurate, and painless scanning alternative to traditional radiation emittance or MRI technology, according to a press release. The company is currently seeking $30 million through a convertible note offering, with US Capital Global Securities, an affiliate of US Capital, as placement agent.
QT Imaging’s first product, the QT Breast Scanner, is FDA-cleared for whole breast imaging and can be used for medical screening and diagnosis. The company’s primary product, QTscan®, has demonstrated in clinical trials to have superior sensitivity and specificity to X-ray mammography and can safely identify the difference between benign and problematic tissue without the need for compression, injections, and potentially harmful radiation. Read more.
